MDXG - MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX
- MiMedx ( NASDAQ: MDXG ) on Monday said it had gotten Japanese approval for the reimbursement of its EPIFIX tissue allograft for the treatment of lower extremity diabetic and venous ulcers.
- The reimbursement decision came from the Japanese Ministry of Health, Labor and Welfare (JMHLW), MDXG said in a statement .
- "Achieving reimbursement was a key pre-requisite to launch EPIFIX in Japan, and we think the awarded rate of 35,100 Yen/cm 2 will be very favorable in supporting market adoption,” said Rohit Kashyap, president of wound care & surgical at MDXG.
- The company believes the Japanese total addressable market associated with the scope of the JMHLW reimbursement decision to be about $500M.
- MDXG stock +4% to $3.67 after hours.
For further details see:
MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX